Company intelligence / Profile preview

Lysando AG

Triesenberg, Liechtensteinlysando.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lysando's lead candidate Art-175 is in preclinical development for Gram-Positive Bacterial Infections. The company has developed over 450 effective prototypes demonstrating Artilysin's potential for treating various bacterial infections.

Therapeutic areas: PulmonologyDermatologyInfectious Diseases
Modalities: Antimicrobial proteins (Artilysin® molecules)
Industry: Biotech

Drug pipeline

1 asset

Artilysin

Pre-clinical

Indications: Bacterial infections, Acne, Atopic dermatitis, Wound infections

Partnerships

AiCuris Anti-infective Cures GmbHAmicogen (South Korea)Bamberg UA (Non-Profit Organization)

Beyond the preview

Go deeper on Lysando AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lysando AG.

Explore the full profile